نتایج جستجو برای: tb vaccine
تعداد نتایج: 133682 فیلتر نتایج به سال:
BACKGROUND Continuous high global tuberculosis (TB) mortality rates and variable vaccine efficacy of Mycobacterium bovis Bacille Calmette-Guérin (BCG) motivate the search for better vaccine regimes. Relevant models are required to downselect the most promising vaccines entering clinical efficacy testing and to identify correlates of protection. METHODS AND FINDINGS Here, we evaluated immunoge...
Approximately 2 million people die of tuberculosis (TB) each year. The current vaccine, Bacille Calmette-Guérin (BCG), albeit widely employed, does not protect against adult pulmonary disease, and new vaccines are urgently needed to reduce the incidence of TB worldwide. New insights into the cellular and molecular mechanisms that underlie the interactions between Mycobacterium tuberculosis and ...
BACKGROUND Novel vaccine strategies are required to provide protective immunity in tuberculosis (TB) and prevent development of active disease. We investigated the safety and immunogenicity of a novel TB vaccine candidate, H4:IC31 (AERAS-404) that is composed of a fusion protein of M. tuberculosis antigens Ag85B and TB10.4 combined with an IC31® adjuvant. METHODS BCG-vaccinated healthy subjec...
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb). Bacille Calmette-Guérin (BCG) the only licensed vaccine against TB, and it effective in children but not adults. The Vaccine Research Team, Department of Microbiology FKUI has developed a DNA-based TB candidate pcDNA3.1-rpfB. This induces immune responses mice, its potency unknown. gold standard for testing challenge method. BSL3 ...
Call it a paradigm shift, a pivot, or a turn – tuberculosis (TB) vaccine research and development (R&D) is entering a period of basic science. After years of focusing on phase II clinical trials, some of the field’s largest players are now redirecting attention and resources to the beginning of the pipeline – basic discovery and preclinical development. This change is motivated by a growing con...
Global eradication of tuberculosis (TB) depends on identification and treatment of all active TB cases and of the two billion people who are estimated to be latently infected with Mycobacterium tuberculosis. The past decade has seen a renaissance of scientific activities and funder investment into development of new TB drugs, diagnostics, biomarkers and vaccines. This viewpoint critically summa...
Objectives Tuberculosis (TB) has still remained a global health issue. One third of the world's population is infected with tuberculosis and the current BCG vaccine has low efficiency; hence, it is necessary to develop a new vaccine against TB. The aim of the current study was to evaluate the efficiency of a novel DNA vaccine encoding Mtb32C-HBHA antigen in inducing specific immune responses ag...
Background: Tuberculosis is a life threatening disease that is partially prevented by BCG vaccine. Development of more effective vaccines is an urgent priority in TB control. Ag85a and Tb10.4 are the members of culture filter protein (CFP) of M. tuberculosis that have high immunogenicity. Objective: To analyze the immunogenicity of Ag85a-Tb10.4 DNA vaccine by enzyme-linked immunosorbent as...
The efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine against pulmonary tuberculosis (TB) varies enormously in different populations. The prevailing hypothesis attributes this variation to interactions between the vaccine and mycobacteria common in the environment, but the precise mechanism has so far not been clarified. Our study demonstrates that prior exposure to live en...
Tuberculosis (TB) kills 2 million people per year and infection with HIV is the most potent known risk factor for progression to active TB. An understanding of the immune response to TB Ags in HIV-infected patients is required to develop optimal TB vaccines and diagnostics. We assessed polyfunctional (IFN-gamma(+)IL-2(+)TNF-alpha(+)) T cell responses to TB Ags in three groups of HIV-1-infected ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید